Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

2,038 questions · 2,118 findings · 339 reviews

No studies found 323 · 15.3%GRADE not reported 166 · 7.8%Very low 552 · 26.1%Low 592 · 28%Moderate 340 · 16.1%High 145 · 6.8%

Vitamin D (higher dose) vs vitamin D (lower dose)

Adverse effect: hypercalciuria As defined by trialists Time frame: 3 months · children under 5 years of age

Vitamin D (higher dose) showed no clear difference in adverse effect: hypercalciuria As defined by trialists Time frame:… compared with vitamin D (lower dose) (low certainty).

1 finding from 1 review

Vitamin D (higher dose) vs vitamin D (lower dose)

Hypercalcaemia · children under 5 years of age

Vitamin D (higher dose) showed no clear difference in adverse effect: hypercalcaemia As defined by trialists Time frame:… compared with vitamin D (lower dose) (low certainty).

1 finding from 1 review

Vitamin D (higher dose) + micronutrient(s) vs vitamin D (lower dose) + micronutrient(s)

Adverse effect: hypercalciuria As defined by trialists Time frame: 3 months · children under 5 years of age

Vitamin D (higher dose) + micronutrient(s) showed no clear difference in adverse effect: hypercalciuria As defined by trialists Time frame: 3… compared with vitamin D (lower dose) + micronutrient(s) (low certainty).

1 finding from 1 review

Vitamin D (higher dose) + micronutrient(s) vs vitamin D (lower dose) + micronutrient(s)

Hypercalcaemia · children under 5 years of age

Vitamin D (higher dose) + micronutrient(s) showed no clear difference in adverse effect: hypercalcaemia As defined by trialists Time frame:… compared with vitamin D (lower dose) + micronutrient(s) (moderate certainty).

1 finding from 1 review

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Metformin · people at increased risk for developing type 2 diabetes
2 findings from 1 review

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Acarbose · people at increased risk for developing type 2 diabetes
2 findings from 1 review

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Repaglinide · people at increased risk for developing type 2 diabetes
2 findings from 1 review